CARLSBAD, Calif., July 25, 2017 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will
host a live webcast on Tuesday, August
8 at 11:30 a.m. Eastern Time
to discuss its second quarter 2017 financial results and report on
pipeline and business progress.
Interested parties may listen to the call by dialing
877-443-5662 or access the webcast at www.ionispharma.com. A
webcast replay will be available for a limited time at the same
address.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading
company in RNA-targeted drug discovery and development focused on
developing drugs for patients who have the highest unmet medical
needs, such as those patients with severe and rare diseases. Using
its proprietary antisense technology, Ionis has created a large
pipeline of first-in-class or best-in-class drugs, with over three
dozen drugs in development. SPINRAZA® (nusinersen) is a
drug that has been approved in the U.S., Europe, Japan
and Canada for the treatment of
spinal muscular atrophy (SMA) in pediatric and adult patients.
Biogen is responsible for commercialization of SPINRAZA. Drugs that
have successfully completed Phase 3 studies include volanesorsen, a
drug Ionis is developing and plans to commercialize through its
affiliate, Akcea Therapeutics, to treat patients with either
familial chylomicronemia syndrome or familial partial
lipodystrophy; and inotersen (IONIS-TTRRx), a drug Ionis
is developing with GSK to treat patients with TTR amyloidosis. Both
drugs are progressing toward regulatory filings in the second half
of 2017. Ionis' patents provide strong and extensive protection for
its drugs and technology. Additional information about Ionis is
available at www.ionispharma.com.
IONIS' FORWARD-LOOKING STATEMENT
This press release
includes forward-looking statements regarding Ionis
Pharmaceuticals' financial position and outlook, Ionis' business,
the business of Akcea Therapeutics, Inc., an affiliate of Ionis
Pharmaceuticals, and the therapeutic and commercial potential of
Ionis' technologies and products in development, including
SPINRAZA, IONIS-TTRRx and volanesorsen. Any statement
describing Ionis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, particularly those
inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around
such drugs. Ionis' forward-looking statements also involve
assumptions that, if they never materialize or prove correct, could
cause its results to differ materially from those expressed or
implied by such forward-looking statements. Although Ionis'
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Ionis. As a result, you are cautioned not to
rely on these forward-looking statements. These and other risks
concerning Ionis' programs are described in additional detail in
Ionis' annual report on Form 10-K for the year ended December 31, 2016, and its most recent quarterly
report on Form 10-Q, which are on file with the SEC. Copies of
these and other documents are available from the Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals,
Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals,
Inc. SPINRAZA™ is a trademark of Biogen.
View original
content:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-hold-second-quarter-2017-financial-results-webcast-300493303.html
SOURCE Ionis Pharmaceuticals, Inc.